ublished in the
"New England Journal of Medicine", a new study reveals: University of
Pennsylvania researchers have confirmed an anti-HIV drugs can reduce the
occurrence of bone marrow transplantation for treatment of leukemia patients risk the chance of complications.
Graft-versus-host disease (GvHD) in 70% of transplant patients tortured and became associated with this treatment of the primary cause of death, the findings in the prevention of graft-versus-host disease areas show a new policy. Allogeneic bone marrow transplantation, also known as stem cell transplantation, which is cleared of cancer-related defensive blood cells and healthy blood cells, will be paired donor blood stem cells to transplant and rebuild the bone marrow of patients.
Prevention of anti-HIV drugs maraviroc GvHD. "Through changes in immune cells may be far from certain sensitive organs to prevent damage in patients with GvHD, our new method makes it possible," an assistant professor of Oncology Department of blood, but also is Penn'sAbramson Cancer Center hematologic malignancies research project members, lead author Dr. RanReshef said, "This is a bone marrow transplant patients to reduce treatment-related complications novel approach, but it does not reduce the patient's immune system, a new cancer-fighting ability." Generally speaking, In transplant patients after transplantation require the use of immunosuppressive drugs to lower the risk of GvHD, GvHD occurs when the new transplanted immune cells of healthy tissue as foreigners and conduct attacks. But when the patient's immune system to accept the graft occurs due to exhausted, those drugs make patients more vulnerable to life-threatening infections and tumor recurrence.
Penn's team found that the use of anti-HIV drug maraviroc treatment can significantly reduce the risk of liver and intestinal organ GvHD incidence, without affecting the immune system function. This involves re-use of maraviroc (2007 was approved for HIV treatment drugs) study represents a breakthrough to prevent GvHD. Reshef and co-author, said the drug right to accept healthy donor stem cells in bone marrow transplant patients is safe. And did not receive the same treatment in patients with maraviroc GvHD incidence compared to a short course of the drug can make patients transplanted after the initial six months time, 73% of severe cases to reduce GvHD.
Graft-versus-host disease (GvHD) in 70% of transplant patients tortured and became associated with this treatment of the primary cause of death, the findings in the prevention of graft-versus-host disease areas show a new policy. Allogeneic bone marrow transplantation, also known as stem cell transplantation, which is cleared of cancer-related defensive blood cells and healthy blood cells, will be paired donor blood stem cells to transplant and rebuild the bone marrow of patients.
Prevention of anti-HIV drugs maraviroc GvHD. "Through changes in immune cells may be far from certain sensitive organs to prevent damage in patients with GvHD, our new method makes it possible," an assistant professor of Oncology Department of blood, but also is Penn'sAbramson Cancer Center hematologic malignancies research project members, lead author Dr. RanReshef said, "This is a bone marrow transplant patients to reduce treatment-related complications novel approach, but it does not reduce the patient's immune system, a new cancer-fighting ability." Generally speaking, In transplant patients after transplantation require the use of immunosuppressive drugs to lower the risk of GvHD, GvHD occurs when the new transplanted immune cells of healthy tissue as foreigners and conduct attacks. But when the patient's immune system to accept the graft occurs due to exhausted, those drugs make patients more vulnerable to life-threatening infections and tumor recurrence.
Penn's team found that the use of anti-HIV drug maraviroc treatment can significantly reduce the risk of liver and intestinal organ GvHD incidence, without affecting the immune system function. This involves re-use of maraviroc (2007 was approved for HIV treatment drugs) study represents a breakthrough to prevent GvHD. Reshef and co-author, said the drug right to accept healthy donor stem cells in bone marrow transplant patients is safe. And did not receive the same treatment in patients with maraviroc GvHD incidence compared to a short course of the drug can make patients transplanted after the initial six months time, 73% of severe cases to reduce GvHD.
"Like real
estate, the total immune response and location, location,
location-related", Reshef said, "The immune system is the body's cells
are not free to move." This is a synchronous process and good harmony,
to the surface of immune cells to express specific receptors and
chemokines with known small protein response occurred. These
inflammatory chemokines bootable immune cells needed to reach their
special organs, or in cases of GvHD patients need a place they cause
damage. We use maraviroc as traffic signals to guide donor immune cells
away from the place where the body may cause GvHD, maraviroc was
originally developed to prevent certain types of HIV from entering
healthy cells in the body.
38 cases of leukemia, including acute myeloid leukemia, myelodysplastic syndrome, lymphomas, bone marrow fibrosis were recruited in this study. All patients received regular GvHD prevention drugs tacrolimus and methotrexate, plus 2 days before transplantation began 33 days maraviroc treatment. The first 100 days after transplantation, maraviroc GvHD patients not appear severe cases of the disease, the bowel or liver GvHD. 6 months, only 6% maraviroc treated patients with severe GvHD, 3% of liver GvHD, 9% appeared GvHD, not in the same maraviroc plus standard medical therapy patients, 6 months after transplantation, the proportion of severe GvHD 22%, liver and intestinal GvHD GvHD were 15% and 27% at 1 year, maraviroc is still part of the lasting benefits, with 29% of patients receiving standard treatment of severe GvHD, the former cumulative severe GvHD incidence rate was 15%. Based on these data, the research team intends longer maraviroc treatment plan for the future, so as to clarify whether it can prolong the protective effect.
Maraviroc shows the different effects of the enterohepatic As expected role of this drug, which is known as T lymphocytes by limiting the immune cells to specific organs of the body movement of the sky effect. Maraviroc blocks the CCR5 receptor thereby preventing cell lymphocytes transported to specific organs. The researchers did not find this drug on the skin GvHD prevention effect, so they envision the skin is compared, CCR5 receptor on lymphocytes recruited to the liver, intestines more important role. Maraviroc treatment for these patients has not increased treatment-related toxicity, has not changed the underlying disease or infection recurrence probability, nor will slow down the body in patients with graft immune system mistakenly believe that the new time
38 cases of leukemia, including acute myeloid leukemia, myelodysplastic syndrome, lymphomas, bone marrow fibrosis were recruited in this study. All patients received regular GvHD prevention drugs tacrolimus and methotrexate, plus 2 days before transplantation began 33 days maraviroc treatment. The first 100 days after transplantation, maraviroc GvHD patients not appear severe cases of the disease, the bowel or liver GvHD. 6 months, only 6% maraviroc treated patients with severe GvHD, 3% of liver GvHD, 9% appeared GvHD, not in the same maraviroc plus standard medical therapy patients, 6 months after transplantation, the proportion of severe GvHD 22%, liver and intestinal GvHD GvHD were 15% and 27% at 1 year, maraviroc is still part of the lasting benefits, with 29% of patients receiving standard treatment of severe GvHD, the former cumulative severe GvHD incidence rate was 15%. Based on these data, the research team intends longer maraviroc treatment plan for the future, so as to clarify whether it can prolong the protective effect.
Maraviroc shows the different effects of the enterohepatic As expected role of this drug, which is known as T lymphocytes by limiting the immune cells to specific organs of the body movement of the sky effect. Maraviroc blocks the CCR5 receptor thereby preventing cell lymphocytes transported to specific organs. The researchers did not find this drug on the skin GvHD prevention effect, so they envision the skin is compared, CCR5 receptor on lymphocytes recruited to the liver, intestines more important role. Maraviroc treatment for these patients has not increased treatment-related toxicity, has not changed the underlying disease or infection recurrence probability, nor will slow down the body in patients with graft immune system mistakenly believe that the new time
No comments:
Post a Comment